Illumina Files New Patent Infringement Suit Against Premaitha Health plc-第四军医大学设备信息网
 首页  公告公示  最新设备  设备共享信息  供应商名录  供应商动态  规章制度  联系我们 
Illumina Files New Patent Infringement Suit Against Premaitha Health plc
2017-09-09 00:00     (浏览者:)

SAN DIEGO--(BUSINESS WIRE)--Sep. 7, 2017-- Illumina, Inc. (NASDAQ:ILMN) announced today that the company has filed a new patent infringement suit against Premaitha Health plc in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom. Illumina is seeking all available remedies, including damages and injunctive relief.

The new suit accuses Premaitha’s IONA® Test of infringing European Patent (UK) 1 524 321 B2 titled, “Non-invasive Detection of Fetal Genetic Traits,” which is exclusively licensed to Illumina from Sequenom, Inc.

Illumina and its wholly owned subsidiary, Verinata Health, Inc., previously filed suits in the UK against Premaitha accusing its Iona test of infringing European Patent (UK) 0 994 963 B2, European Patent (UK) 1 981 995 B1, European Patent (UK) 2 183 693 B1, European Patent (UK) 2 385 143 B1 and European Patent (UK) 2 514 842 B1. Those suits remain pending.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit and follow @illumina.

Source: Illumina, Inc.

Illumina, Inc.
Rebecca Chambers, 858-255-5243
Eric Endicott, 858-882-6822

上一条:Illumina to Announce Third Quarter 2017 Financial Results on Tuesday, October 24, 2017
下一条:Illumina and Telegraph Hill Partners Launch Verogen, Inc. to Drive Adoption of Next-Generation Sequencing in the Global Forensic Genomics Market

第四军医大学训练部教保处  地址:陕西省西安市长乐西路169号
电话:029-84774344  邮编:710032